Parr MK - Search Results

1

Comparison of middle- and bottom-up mass spectrometry in forced degradation studies of bevacizumab and infliximab.

Dyck YFK, Rehm D, Winkler K, Sandig V, Jabs W, Parr MK. Dyck YFK, et al. Among authors: parr mk. J Pharm Biomed Anal. 2023 Oct 25;235:115596. doi: 10.1016/j.jpba.2023.115596. Epub 2023 Jul 22. J Pharm Biomed Anal. 2023. PMID: 37540995 Review.

2

Novel approach to supercritical fluid chromatography-mass spectrometry analysis of metal ions using EDTA complexation.

Plachká K, Bredendiek F, Nováková L, Parr MK. Plachká K, et al. Among authors: parr mk. Anal Chim Acta. 2023 Dec 1;1283:341955. doi: 10.1016/j.aca.2023.341955. Epub 2023 Oct 24. Anal Chim Acta. 2023. PMID: 37977781

3

Analysis of doping control samples using supercritical fluid chromatography-tandem mass spectrometry: Ready for routine use.

Wuest B, Gavrilović I, Cowan D, Torre X, Botrè F, Parr MK. Wuest B, et al. Among authors: parr mk. J Sep Sci. 2023 Apr;46(7):e2200880. doi: 10.1002/jssc.202200880. Epub 2023 Feb 25. J Sep Sci. 2023. PMID: 36739523

4

Controlling the elution order of insulin and its analogs in sub-/supercritical fluid chromatography using methanesulfonic acid and 18-crown-6 as mobile phase additives.

Neumann J, Schmidtsdorff S, Schmidt AH, Parr MK. Neumann J, et al. Among authors: parr mk. J Sep Sci. 2023 Nov;46(22):e2300520. doi: 10.1002/jssc.202300520. Epub 2023 Sep 29. J Sep Sci. 2023. PMID: 37775313

5

Ternary eluent compositions in supercritical fluid chromatography improved fingerprinting of therapeutic peptides.

Neumann J, Schmidtsdorff S, Schmidt AH, Parr MK. Neumann J, et al. Among authors: parr mk. J Sep Sci. 2023 Mar;46(5):e2201007. doi: 10.1002/jssc.202201007. Epub 2023 Jan 10. J Sep Sci. 2023. PMID: 36601991

6

Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?

Schmidtsdorff S, Neumann J, Schmidt AH, Parr MK. Schmidtsdorff S, et al. Among authors: parr mk. Arch Pharm (Weinheim). 2023 Feb;356(2):e2200484. doi: 10.1002/ardp.202200484. Epub 2022 Dec 2. Arch Pharm (Weinheim). 2023. PMID: 36461687

7

Combinatory in vitro effects of the β2-agonists salbutamol and formoterol in skeletal muscle cells.

Piribauer M, Jiang L, Kostov T, Parr M, Steidel S, Bizjak DA, Steinacker JM, Diel P. Piribauer M, et al. Toxicol Lett. 2023 Apr 1;378:10-18. doi: 10.1016/j.toxlet.2023.02.007. Epub 2023 Feb 21. Toxicol Lett. 2023. PMID: 36822333

8

Testing anabolic activity, potency and mechanisms of action of the phyto-derived beta 2 agonist higenamine.

Jiang L, Piribauer M, Kostov T, Steidel S, Bizjak DA, Steinacker JM, Parr M, Diel P. Jiang L, et al. Toxicol Lett. 2023 Aug 15;385:21-28. doi: 10.1016/j.toxlet.2023.08.007. Epub 2023 Aug 19. Toxicol Lett. 2023. PMID: 37598871

9

A disruptive clickable antibody design for the generation of antibody-drug conjugates.

Rakotoarinoro N, Dyck YFK, Krebs SK, Assi MK, Parr MK, Stech M. Rakotoarinoro N, et al. Among authors: parr mk. Antib Ther. 2023 Oct 26;6(4):298-310. doi: 10.1093/abt/tbad023. eCollection 2023 Oct. Antib Ther. 2023. PMID: 38107665

10

Acute Effects of Single Versus Combined Inhaled β2-Agonists Salbutamol and Formoterol on Time Trial Performance, Lung Function, Metabolic and Endocrine Variables.

Bizjak DA, Nussbaumer D, Winkert K, Treff G, Takabajashi K, Mentz L, Schober F, Buhl JL, John L, Dreyhaupt J, Steeb L, Harps LC, Parr MK, Diel P, Zügel M, Steinacker JM. Bizjak DA, et al. Among authors: parr mk. Sports Med Open. 2023 Aug 28;9(1):79. doi: 10.1186/s40798-023-00630-3. Sports Med Open. 2023. PMID: 37640958 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127 results

Search Page